论文信息 - Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial - 字舞流文

Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial

P. Neven | Y. Hotko | H. Denys | Z. Horváth | Z. Nowecki | C. Morrow | T. Klinowska | Mafalda Oliveira | C. Zamagni | J. Lindemann | E. Hamilton | G. Nemsadze | F. Forget | Delphine Lissa | Y. Kulyaba | T. Melkadze | Zuzana Traugottová | Alastair Mathewson | E. Arkania | M. Bennett | Denys Pominchuck | T. Andabekov | Yuriy Semegen | Vladmir Vladmirov | A. Nesterova | Bistra Kirova | Ruaan Van Zyl